Background and purpose
Introduction
N-methyl-D-aspartate receptors (NMDARs) are the most complex glutamate-gated ionotropic receptor in the CNS. They play a key role in the excitatory synaptic transmission and many brain functions, such as memory and cognition. Because of their involvement in various brain pathologies, including ischemia, neurodegenerative and neuropsychiatric disorders, NMDA receptors attract a great deal of interest in therapeutic research (Lipton, 2006; Paoletti and Neyton, 2007) .
There is a great diversity in the NMDAR subtypes. It is widely accepted that functional NMDARs are tetrameric complexes assembled of the two obligatory GluN1 subunits combined with one or two GluN2(A,B,CD) and/or GluN3(A,B) subunits (Matsuda et al., 2003; Furukawa et al., 2005; Paoletti and Neyton, 2007) . Subunit composition determines specific pharmacological and biophysical properties of NMDARs such as glutamate affinity, receptor desensitization, pharmacological sensitivity, and channel block by extracellular Mg 2+ (Cull-Candy and Leszkiewicz, 2004; Paoletti and Neyton, 2007) . GluN2 and GluN3 subunit expression exhibits regional specificity and undergoes developmental regulation (Monyer et al., 1994; Cull-Candy and Leszkiewicz, 2004; Paoletti and Neyton, 2007; Henson 2010) .
Until recently, attention has been focused on the role of NMDARs in neuronal function. The functional expression of NMDA receptors in glia was unappreciated for a long time. Because of the voltage-dependent Mg
2+
-block, NMDA receptors were expected to be inactive at physiological resting potential in non-excitable glial cells. It has been reported only recently that glial cells, namely oligodendrocytes (Karadottir et al., 2005; Micu et al., 2006) and cortical astrocytes (Lalo et el., 2006) , express functional NMDA receptors that have distinct biophysical properties and may be composed of subunits different from GluN2A and GluN2B. Most importantly, glial NMDARs exhibit the weak Mg 2+ -block at physiological concentrations (Karadottir et al., 2005; Lalo et al. 2006 ) and therefore can be 5 active even at resting membrane potential. We have previously shown that astroglial NMDA receptors mediate transmembrane currents in cortical astrocytes activated upon physiological synaptic transmission (Lalo et el., 2006) .
Recent studies linking glial NMDARs to various neurological disorders ignited an interest in them as
promising targets for the development of new therapeutic agents (Lipton, 2006; Matute et al., 2006) .
Finding specific antagonists of astroglial NMDAR receptors could allow the selective modulation of astroglial signaling without directly affecting neurons. This would be very useful for the investigation of the mechanisms of astroglial modulation of synaptic transmission and plasticity. However, study of the pharmacological profile of glial NMDARs is far from complete.
We tested the sensitivity of astroglial NMDARs to the novel antagonist UBP141 reportedly exhibiting selectivity over different GluN2 subunits (Morley et al., 2005; Brothwell et al., 2008) . We also tested the action of memantine -a therapeutically used antagonist which was reported to have substantially different affinity for GluN2A/B and GluN2C/D-containing receptors in physiological concentrations of extracellular Mg 2+ (Kotermanski and Johnson, 2009 ).
Methods

Slice and cell preparation
Experiments were performed on transgenic mice expressing enhanced green fluorescent protein (EGFP) under the control of the human glial fibrillary acidic protein (GFAP) promoter (line TgN(GFAP-EGFP)GFECFKi; see Nolte et al., 2001; Lalo et al., 2006) . Mice (4 -8 weeks old) were anaesthetized by halothane (1.5-1.8 vol %) and then decapitated, in accordance with UK legislation. Slices were prepared using the technique described previously (Lalo et al., 2006) . Brains were rapidly dissected in physiological saline containing (in mM): 135 NaCl, 3 KCl, 3 MgCl 2 , 0.5 CaCl 2 , 26 NaHCO 3 , 1 NaH 2 PO 4 , 15 glucose, pH 7.4 when gassed with 95% O 2 / 5%CO 2 . Brain slices (280 -300 µm thick) were cut at 4 o C and kept at room temperature for 1 -4 h prior to in situ recordings and cell isolation in the above solution but with (mM) CaCl 2 2.5 , MgCl 2 1.
The same extracellular solution was used for recordings in slices.
Astrocytes and neurons were acutely isolated from somatosensory cortex layer II/III using the modified "vibrating ball" technique (Pankratov et al., 2002; Lalo et al., 2006) . The glass ball (200 µm diameter)
was moved slowly some 10 -50 µm above the slice surface, while vibrating at 100 Hz (lateral displacements 20 -30 µm). The composition of external solution for isolated cell experiments was (mM):
135 NaCl; 2.7 KCl; 2 CaCl 2 ; 1 MgCl 2 ; 10 HEPES, 1 NaH 2 PO 4, 15 glucose, pH adjusted with NaOH to 7.3. In some experiments, the extracellular CaCl 2 concentration was elevated to 20 mM.
Electrophysiology
Cells were initially identified by size and the shape of somata under IR gradient contrast and green fluorescence (astrocytes). After establishing the whole-cell recording configuration, identification of cells was verified by their response to a series of depolarizing and hyperpolarizing voltage steps from a holding potential of -80 mV (Lalo et al., 2006) . All cells identified visually by EGFP fluorescence demonstrated an electrophysiological signature characteristic of astrocytes, i.e series of passive currents with nearly linear I-V relationship, whereas cells identified as pyramidal neurons exhibited prominent rapidly-activating currents elicited by depolarization as described previously in (Lalo et al., 2006) .
Whole-cell voltage clamp recordings from the cortical astrocytes and pyramidal neurons were made with patch pipettes (5 -6 M) filled with intracellular solution (in mM): 110 KCl, 12 NaCl, 10 HEPES, 5
MgATP, 0.2 EGTA, pH 7.35. The membrane potential was clamped at -80 mV in the astrocytes and at -40 mV in the neurons unless stated otherwise. Currents were monitored using an AxoPatch200B patchclamp amplifier (Axon Instruments) filtered at 2 kHz and digitized at 4 kHz. Experiments were controlled by PCI-6229 data acquisition board (National Instruments) and WinFluor software (Strathclyde Electrophysiology Software); data were analyzed by custom-designed software.
Liquid junction potentials were measured with the patch-clamp amplifier; all voltages reported were corrected accordingly. Series resistances were 5-12 M and input resistances were 50-150 MΩ for astrocytes and 400-900 MΩ for neurons; both varied by less than 20% in the cells accepted for analysis.
A modified "square-pulse" concentration jump method (Pankratov et al., 2002; Lalo et al., 2006) was used for rapid applications of solutions containing various agents to the acutely isolated cells. Unless stated otherwise, transmembrane currents were evoked in acutely isolated cortical neurons and astrocytes by application of 50 µM NMDA and 1µM glycine. Antagonists of NMDA receptors were preapplied for 2 min before application of agonist. Between agonist applications, cells were constantly perfused with agonist-free extracellular solution using gravity-fed bath application (flow rate 1-1.5 ml min -1 ). Responses of the cortical neurons and astrocytes to glycine were recorded in presence of 10 μM strychnine and 100 μM picrotoxin.
To examine the synaptic currents in situ, voltage-clamp recordings were made from identified astrocytes and pyramidal neurons situated in the somatosensory cortex layer II/III at temperature of 30-32 0 C.
Axons originating from layer IV-VI neurones were stimulated at 0.15 Hz with a bipolar coaxial electrode (WPI, USA) placed in the layer IV approximately opposite the site of recording. Stimuli were single pulses (300 µs) of magnitude adjusted to produce a synaptic current in neurons that was 30-40% of the maximal response (typically, stimulus amplitude was 5-7 μA). At such stimulus strength the amplitude of response in the astrocytes reached 25-30% of maximal.
To isolate the NMDA receptor-mediated components of glial and neuronal currents activated by synaptic stimulation, cortical slices were treated with the following pharmacological agents: picrotoxin 100 µM, a combination of the inhibitors of glutamate transporters (Danbolt, 2001; Hu et al., 2003) Benzyloxyaspartic acid (DL-TBOA), 30 µM; an antagonist of AMPA receptors, 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX), 50 µM; the P2X receptor antagonist pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid tetrasodium salt (PPADS), 30 µM. According to our previous reports (Lalo, et al. 2006; Lalo et al., 2008) these concentrations of antagonists effectively inhibited P2X, AMPA receptors and glutamate transporters expressed in the cortical astrocytes and neurons.
Fluorescent Ca
2+ -imaging
To monitor intracellular Ca
2+
, cortical astrocytes were loaded with 150 µM Fluo-3 through the whole-cell patch-pipette (substituting the EGTA in the intracellular saline). Cells were illuminated at 495 nm using the OptoScan monochromator (Cairn, UK), fluorescence was measured at 530±20 nm.
The fluorescent images were recorded using an Olympus BX51 microscope with an UMPLFL20X/NA0.95 objective and 2X intermediate magnification and an iXon885 EMCCD camera (Andor Technology, UK); exposure time was 35 ms at 2X2 binning. Elevation in the intracellular Ca 2+ level was evaluated by ΔF/F 0 ratio after background subtraction.
Data analysis
Data on the concentration-dependence of the effects of antagonists were fitted with the following:
, where I is the current measured with drug concentration [B] , I 0 is the current in control conditions, and p is a Hill coefficient. The relative calcium permeability of NMDA receptors was calculated from the reversal potential of NMDA-activated current in the context of the extended Goldman-Hodgkin-Katz theory as described previously (Lewis 1979; Mayer and Westbrook, 1987; Pankratov et al., 2002) . Briefly, the current-voltage relationships of NMDA-response were normalised to the amplitude at -40 mV, averaged over all cells and fitted with a polynomial curve to determine a reversal potential. The permeability ratios for Ca 2+ to Na + (P Ca /P Na ) and Na + to K + (P Na /P K ) were calculated from values of reversal potential at two different extracellular calcium concentrations converted to the activities in the electrolyte solutions (Mayer and Westbrook, 1987; Castro and Albuquerque, 1995) ; the following activity coefficients were used: 0.77 for Na + and K + , 0.29 and 0.26 for low and high concentrations of Ca
2+
.
Drugs
UBP141 was purchased from Ascent Scientific (UK), other receptor antagonists were from the Tocris Bioscience, other salts and chemicals were from Sigma (Dorset, UK).
Results
Agonist-evoked currents in acutely isolated astrocytes and neurons
Recordings from visually-identified acutely isolated fluorescent astrocytes were made within 20-50 min after isolation. Taking into account the competitive mechanism of UBP141 action (Morley et al., 2005) we activated astrocytic NMDA receptors by saturating concentration of NMDA (50µM, see Lalo et al., 2006; Erreger et al., 2007) . Application of 50 µM NMDA with 1µM glycine at a holding potential -80 mV
) evoked inward currents in all of 58 astrocytes tested (Fig.1A ). Functional properties of NMDA-activated currents, i.e slow desensitization kinetics, high affinity to agonist, sensitivity to D-AP5 and lack of Mg 2+ block were similar to our data reported previously for cortical astrocytes (Lalo et al., 2006, see also Fig.4A ). Contrary to the astrocytes, L2/3 pyramidal neurons did not respond to NMDA at holding potential of -80 mV due to Mg 2+ -block; currents elicited by NMDA in the pyramidal neurons at other holding potentials had functional properties very similar to NMDA receptors in hippocampal and cortical neurons (Mayer and Westbrook, 1987; Lalo et al.,2006 , see also Fig.4B ).
Unless stated otherwise, all experiments reported below were carried out at holding potential -80 mV in astrocytes and at -40 mV in neurons.
UBP141, novel subunit-selective antagonist of NMDA receptors, had different inhibitory action in astrocytes and neurons ( Fig.1) . Pre-incubation with 3 µM UBP141 for 2 min decreased the amplitude of NMDA-evoked responses (Fig.1A) in the astrocytes by 62 ± 14% (n=7) whereas neuronal responses ( (Morley et al., 2005) .
We also tested the inhibitory action of another subunit-selective NMDAR antagonist -ifenprodil.
Incubation with 10 µM ifenprodil did not significantly affect the amplitude of NMDA-activated currents in the cortical astrocytes (3±7% decrease; n=15, P > 0.05, one-population t-test; data not shown). In contrast, the same concentration of ifenprodil inhibited the NMDA-response in cortical neurons by 58±11% (n=6, data not shown). The absence of notable effect of ifenprodil on NMDA-response in the astrocytes indicates low level (if any) expression of GluN2B subunits. This result is slightly different from our previous data (Lalo et al. 2006 ) obtained in younger mice (17-22 day-old), where we observed partial (less than 50%) inhibition of NMDA receptors by 10 µM ifenprodil in the sub-population (about 30%) of cortical astrocytes. The expression of both GluN2B and GluN2C subunits in the mouse cortical astrocytes, also in younger age, has been reported by Schipke et al. (2001) . The variation in the subunit composition of astroglial NMDARs may be related to developmental changes, like it happens in neurons where decrease in the expression of GluN2B and increase in the expression of GluN2C subunit have been reported (Henson et al. 2010; Steinert et al. 2010) . Also, the pathologically evoked expression of GluN2B subunit might occur in the astrocytes in some cases after ischemic insults during tissue preparation, as it has been observed by (Krebs et al. 2003) .
Dramatic difference in the inhibitory action of UBP141 suggests different subunit composition of NMDA receptors in cortical astrocytes and neurons, presumably lack of GluN2A and B subunits and incorporation of GluN2C or D subunits in astroglial NMDARs. This hypothesis was supported by data on the inhibitory action of memantine (Fig.2) . Taking into account that action of memantine on NMDA receptors depends on membrane potential and extracellular Mg 2+ concentration (Wrighton et al., 2008; Kotermanski and Johnson, 2009 ), we measured effect of memantine on astroglial and neuronal receptors at physiological Mg 2+ concentrations and membrane potentials at which these receptors would likely be activated during physiological activity, correspondingly -80 mV and -40 mV. Preapplication of 1 µM and 10 µM memantine decreased the amplitude of NMDA-evoked currents in the astrocytes ( Fig.2A ) by 39 ± 12% and 72±7% respectively (n=7). However, neuronal responses to NMDA (Fig.2B) were correspondingly inhibited by 7±11% and 46±10% (n=6).
Memantine exhibited different affinities for glial and neuronal NMDA receptors ( 
Synaptically-activated currents in cortical astrocytes and neurons in situ
Results obtained in the acutely-isolated cells were corroborated by data on the pharmacological sensitivity of NMDA receptor-mediated components of synaptic response in astrocytes and neurons in brain slices. We performed voltage-clamp recordings from protoplasmic astrocytes and pyramidal neurons in layer II/III of somato-sensory cortex of EGFP/GFAP mice (Nolte et al., 2001) . The astrocytes in acutely prepared brain slices were identified by green fluorescence and by their characteristic electrophysiological signatures (see Methods).
Stimulation of neuronal afferents originating from layers IV-VI in presence of 100 µM picrotoxin induced excitatory postsynaptic currents (EPSCs) in neurons and transmembrane ion currents in the astrocytes (Fig.3 , see also Lalo et al., 2006) . Ion currents induced in the astrocytes were directly associated with synaptic transmission because (i) treatment of slices with 1 M TTX completely abolished glial responses, (ii) the amplitude of the glial response was stimulus-dependent in a manner similar to the synaptic current evoked in the neighboring neurons and (iii) latency time of glial responses was the same as latency of EPSCs (1.5-2.5 ms). Therefore, we identified astroglial responses as glial synaptic currents (GSCs). As it has been shown before (Lalo et al., 2006) , the major part of cortical GSC is mediated by glial NMDA receptors and glutamate transporters. Also, AMPA and P2X receptors can participate in ionotropic signaling in cortical astrocytes (Lalo et al., 2006 , Lalo et al., 2008 . As we have discussed previously (Lalo et al., 2006) , astrocytic GSCs most likely result from both spill-out of neurotransmitter from cortical synapses and ectopic release similarly to Bergmann glial cells (Matsui and Jahr, 2004) . Cortical astrocytes may also be a direct target of axon collaterals, like NG2+ glial cells in hippocampus and cerebellum (Bergles et al., 2009) .
To Similar to NMDA-activated currents in the acutely isolated cells, NMDA receptor-mediated synaptic responses in astrocytes and neurons in situ exhibited different sensitivity to UBP141, ifenprodil and memantine (Fig.3) . Application of 3 µM UBP141 to cortical slices decreased the amplitude of astrocytic GSCs by 58±6% (n=9), which recovered after washout of UBP141. However, consecutive application of ifenprodil (10 µM) did not cause notable effect on astrocytic NMDA receptors (Fig.3A) . In contrast, application of 3 µM UBP141 decreased the amplitude of neuronal EPSCs only by 8±6% whereas ifenprodil inhibited EPSCs by 63±9% (n=9).
Application of memantine confirmed the differential sensitivity of astrocytic and neuronal response to NMDA. Memantine (1 µM and 10µM; Fig.3B ) reversibly inhibited astrocytic GSCs by 41±8% and 81±6% respectively (n=8). However, 1 µM memantine had no effect on neuronal EPSCs (inhibition by 5±6%; P > 0.05, one-population t-test), whilst the 10 µM memantine inhibited EPSCs by 49±8% (n=8). These results confirm that action of UBP141 and memantine was due to direct inhibition of astrocytic NMDA receptors. The small residual GSC (2±4%, n=10) remaining in presence of antagonists of NMDA receptors and glutamate transporters may, however, be associated with redistribution of the extracellular potassium in the vicinity of the astroglial membrane.
It is worth to note that inhibitory effects of UBP141 and memantine observed in astrocytes and neurons in situ closely agree with data obtained in acutely isolated cells. Importantly, our results demonstrate the feasibility of selective pharmacological modulation of NMDA receptor-mediated signalling in neurons and astrocytes in physiological conditions.
Functional properties and subunit composition of astroglial NMDARs
The above results suggest incorporation of GluN2C/D subunits in NMDA receptors expressed in cortical astrocytes. Although GluN2C/D subunits have low affinity to Mg 2+ than GluN2A/B, they are still blocked by physiological concentrations (>0.5 mM) of Mg 2+ (Qian and Johnson, 2006) . In contrast, NMDARs containing one or two GluN3 subunits were shown to have much lower sensitivity to Mg 2+ -block at physiological concentrations (Sasaki et al. 2002; Tong et al. 2008; Henson et al., 2010) . Incorporation of GluN3 subunits, however, renders much lower calcium permeability to the NMDARs.
Taking into account the importance of Ca
2+
-signalling for the physiological activity of glial cells, we evaluated Ca
-permeability of astroglial NMDARs using the Goldman-Hodgkin-Katz theory (see Methods). The reversal potential of NMDA-induced currents in the isolated cortical astrocytes in 2 and 20 mM extracellular Ca 2+ was 0.92±0.89 mV and 7.5±2.4 mV (n=7) respectively (Fig.4) . The corresponding values for the neuronal NMDA-responses were 2.75±0.97 mV and 14.1±2.8 mV (n=6). The permeability ratio P Ca /P Na calculated from the reversal potential of NMDA-mediated current was 3.4 for astrocytes and 7.5 for neurons.
The obtained P Ca /P Na ratio for the NMDARs in cortical neurons agrees with data reported previously for neuronal NMDARs and various heterologously expressed GluN1/GluN2 subunit combinations (Mayer and Westbrook, 1987; Lino et al., 1990; Matsuda et al., 2003; Tong et al., 2008) . On the other hand, our evaluation of the relative Ca 2+ -permeability of astroglial NMDARs is very close to the results of recent studies of GluN3 subunit-containing receptors (Sasaki et al., 2002; Matsuda et al., 2003; Tong et al., 2008) . It should be emphasized that even though the Ca 2+ -permeability of astroglial NMDA receptors is lower compared to neuronal NMDARs, it is close to the permeability of other ionotropic receptors, like neuronal nicotinic ACh receptors (P Ca /P Na ≈2.1-6.1) or P2X1 (P Ca /P Na =3.9) and P2X2 (P Ca /P Na =2.2) receptors (Castro and Albuquerque, 1995; Evans et al., 1996; Fucile 2004) and is larger than the permeability of Ca 2+ -permeable kainate (P Ca /P Na =0.74) and AMPA (P Ca /P Na ≈0.5-1.7) receptors (Burnashev et al., 1996; Isa et al., 1996) . -permeability strongly suggests the presence of the GluN3 subunit in glial NMDARs. Accordingly, the expression of pure di-heteromeric GluN1/GluN3 receptors in cortical astrocytes cannot be ruled out a priori. The most characteristic property of such receptors is a capability to be activated by application of glycine or D-serine in the absence of glutamate. We found that glycine and D-serine acted as weak agonists, inducing inward currents of much smaller amplitude than currents induced by NMDA or glutamate, in all 10 astrocytes tested (Fig.6 ). This contrasts with the much higher potency of glycine that one would expect of pure GluN1/GluN3 receptors (Chatterton et al., 2002; Henson et al., 2010) . We also observed potentiation of NMDA-activated currents in astrocytes by 10 µM D-serine (Fig.6) , this is in contrast to the D-serineinduced desensitization of GluN1/GluN3 receptors reported previously (Chatterton et al., 2002) . On the other hand, partial agonistic action of glycine in the cortical astrocytes closely agrees with data reported for GluN1/ GluN2A/GluN3B tri-heteromeric receptors (Cavara and Hollmann, 2008) .
To elucidate whether currents activated in the cortical astrocytes by glycine and D-serine were mediated by di-heteromeric or tri-heteromeric receptors, we tested their sensitivity to NMDA receptor antagonists. Weak block by classic NMDA antagonists is a characteristic feature of GluN1/GluN3 receptors whereas triplet GluN1/GluN2/GluN3 receptors can be blocked by antagonists targeting GluN2 subunits (Sasaki et al., 2002; Smothers and Woodward, 2010; Henson et al. 2010) . MK-801 (10 µM), memantine (10 µM) and UBP141 (10 µM) showed strong inhibitory action on the response of astrocytes to glycine (Fig.7A ) and D-serine (Fig. 7B) . Inhibitory effects NMDAR antagonists on glycine and D-serineactivated currents in the astrocytes did not differ significantly from their action on NMDA-activated currents ( Fig. 7C) indicating that di-heteromeric GluN1/GluN3 receptors bring a little contribution to glutamatergic signalling in cortical astrocytes. Taken together, our results suggest that NMDA receptors in cortical astroglia are assembled from GluN1, GluN2 and GluN3 subunits.
Discussion
Our results demonstrate striking difference in the properties of astrocytic and neuronal NMDA receptors. Moreover, our findings provide several clues to identify the subunit composition of astroglial
NMDARs. There is no doubt that glial NMDARs contain two GluN1 subunits that are essential for trafficking to the membrane (Matsuda et al., 2003; Furukawa et al., 2005) . In di-and tri-heteromeric NMDARs, expression of certain types of GluN2A-D subunits confers sensitivity to selective antagonists, such as D-AP5 or ifenprodi (Paoletti and Neyton, 2007) . Hence, the most feasible explanation for the high affinity of astroglial receptors to UBP141 and memantine and their low sensitivity to ifenprodil is incorporation of GluN2C or GluN2D subunits. This hypothesis is also corroborated by very high potency of glutamate and NMDA to astroglial NMDARs to (Lalo et al., 2006) which is close to the data reported for recombinant GluN1/GluN2D receptors (Erreger et al., 2007) .
At the same time, glial NMDA receptors have a very low sensitivity to Mg 2+ -block, as has been shown already in (Lalo et al., 2006) and confirmed again in our present experiments. The only type of NMDA subunits, insensitive to Mg 2+ in physiological concentrations is the GluN3 subunit. The stoichiometry of astroglial NMDARs might be different however, with incorporation of either one or two GluN3 subunits (Henson et al., 2010) . The functional expression of GluN1/GluN3 di-heteromeric receptors has been suggested for cerebrocortical neurons (Chatterton et al., 2002) ; white matter oligodendrocytes have been shown to express tri-heteromeric receptors (Karadottir et al., 2005; Burzomato et al. 2010 ).
The most peculiar feature of di-heteromeric GluN1/GluN3 receptors is their capability to be activated by glycine and, arguably, D-serine with higher potency than glutamate that even gave rise to the alternative term "excitatory glycine receptors" (Chatterton et al., 2002) . These properties do not agree with our observations: we did not observe a high potency of glycine and D-serine in the activation of inward currents in the cortical astrocytes (Fig.6) . We observed potentiation of NMDA-activated currents by D-serine (Fig.6 ) not desensitization, which is not expected for GluN1/GluN3 assembly (Henson et al., 2010) . Furthermore, both NMDA-activated currents and responses to glycine and D-serine were strongly inhibited by D-AP5 (Lalo et al., 2006) , memantine (Fig.2,3 ) and MK-801 (Fig.4 and 7) . Thus, the pharmacological profile of NMDA-mediated responses in cortical astrocytes does not allow attributing them purely to di-heteromeric GluN1/GluN3 receptors.
The only structural composition that can explain all pharmacological and functional properties of the astroglial NMDARs we describe here is a tri-heteromer incorporating, in addition to two GluN1 subunits, one of GluN2C or D subunit and one GluN3 subunit, rendering astroglial receptors much less sensitive to Mg 2+ but sensitive to UBP141, memantine and D-AP5 (Fig.1, 3 and 7) . This suggestion is supported by the weak Mg
2+
-block observed for tri-heteromeric GluN1/GluN2/GluN3 receptors (Sasaki et al., 2002; Tong et al., 2008) . It is also in line with evidence of expression of GluN2C, GluN2D and GluN3 subunits in white matter oligodendrocytes (Karadottir et al., 2005; Burzomato et al., 2010) .
It is worth to note that astroglial NMDARs showed lower sensitivity to Mg 2+ -block than GluN1/GluN2C/GluN3A receptors in oligodendrocytes (Karadottir et al., 2005; Burzomato et al., 2010) .
This might be explained by incorporation of different splice variants of GluN1 and GluN2 subunits and/or incorporation of GluN3B subunit. It has been shown that co-assembly of GluN3 with different splice variants of GluN1 subunit can affect functional properties of di-heteromeric receptors (Cavara et al., 2009; Smothers and Woodward, 2009 ). In particular, fractions of glycine-activated currents blocked by Mg 2+ in the receptor complexes assembled with GluN1-2b and GluN1-3b were much lower than in the receptors containing other GluN1 variants (Cavara et al., 2009) . Futhermore, degree of Mg 2+ -block of almost all isoforms of GluN1/GluN3B receptors (Cavara et al., 2009) was lower than Mg 2+ -block reported for GluN1/GluN3A receptors (Chatterton et al., 2002) . It has also been reported recently that splicing of GluN2A subunit can lead to loss of Mg 2+ -block (Endele et al., 2010 (Henson et al., 2010) , the molecular structure of glial NMDARs is worth further investigation.
The other important finding of the present study is the difference in the affinity of glial and neuronal
NMDARs to memantine in physiological concentrations of Mg
. The recent successes of memantine in treatment of Alzheimer's disease revived interest in the therapeutic use of NMDA antagonists (Lipton, 2006) . Our findings strongly support the conclusions of Kotermanski and Johnson (2009) 
that neuronal
NMDARs can have much lower affinity to memantine in physiological conditions than was previously thought and that the clinical effects of therapeutic doses of memantine are most likely related to its action on GluN2C/D-rather than on GluN2A/B-containing receptors. Furthermore, our results suggest that those GluN2C and D subunits, which might underlie the therapeutic effects of memantine, may be mediated via astroglial NMDA receptors.
We have shown that the substantial difference in pharmacological and biophysical properties of astroglial and neuronal NMDARs enables the selective modulation of synaptically-driven astrocytic signalling. This may be very useful for elucidating the mechanisms of neuron-glia communications and development of novel therapeutic agents specifically targeting glial signalling. Note the significant contribution made by the NMDA receptors to glutamatergic Ca 2+ -signal in the astrocytes. (C) Pooled data (mean ± SD for 10 astrocytes and 7 neurons) of amplitude of current activated by glycine, D-serine and NMDA and D-serine together; amplitudes were normalized to the amplitude of NMDA-activated current.
Legends for Figures
Recordings were made at a holding potential of -80 mV in the astrocytes and -40 mV in the neurons.
Note the weak agonist action of glycine and D-serine in the astrocytes. (C) Pooled data (mean ± SD for 5 astrocytes) on the inhibitory effect of MK801, memantine and UBP141 on astrocytic responses. Although glycine-activated currents exhibited less sensitivity to antagonists than NMDAactivated currents, the difference was not statistically significant.
All recordings were made at a holding potential of -80 mV in presence of picrotoxin and strychnine.
. 
